Αρχική World News FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of... World News FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Από Ogkologos - 23 Μαρτίου, 2026 621 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cancer Research UK thanks Tania Bryer for a decade of fundraising... 19 Απριλίου, 2022 ESMO Calls for the European Commission to Propose an EU Directive... 7 Οκτωβρίου, 2026 Jimmy Carter Signed This Treaty Demanding An End To Violence Against... 7 Μαΐου, 2021 Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 12 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer What Is Mindfulness and How Can It Help People With Cancer? Working to Close the Cancer Screening Gap Caused by COVID Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not...